Form 4: Aquestive Therapeutics Director Timothy E. Morris Acquires 38,000 Stock Options

Director Timothy E. Morris of Aquestive Therapeutics, Inc. acquired 38,000 stock options on June 20, 2024, exercisable for common stock.

Summary

• On June 20, 2024, Timothy E. Morris, a director of Aquestive Therapeutics, Inc., acquired 38,000 stock options.
• The options have an exercise price of $2.50.
• The options vest on June 25, 2025, contingent upon Mr. Morris's continued service with the company.
• The options expire on June 20, 2034.
• Following the transaction, Mr. Morris directly owns 38,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It simply reports a transaction and doesn't inherently convey positive or negative sentiment.

Future Outlook

The vesting of the options is contingent upon Mr. Morris's continued service with Aquestive Therapeutics, indicating an incentive for him to remain with the company.

Industry Context

This is a standard Form 4 filing, reflecting insider transactions. Stock options are a common form of executive compensation in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, used to align management's interests with those of shareholders.
• The vesting schedule of approximately one year is fairly standard.
• Comparing the size of this grant to similar companies would require analyzing their executive compensation policies and market capitalization.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of shareholders, as the value of the options is tied to the company's stock performance.

Key Dates